<p>LivaNova（纳斯达克代码：LIVN - 获取免费报告）于周三发布了其财报。公司报告本季度每股收益为 0.98 美元，超出分析师一致预期的 0.85 美元，超出幅度为 0.13 美元，Briefing.com 报道。公司本季度收入为 3.623 亿美元，而一致预期为 3.4605 亿美元。LivaNova 的股本回报率为 16.54%，净利润率为-17.46%。与去年同期相比，LivaNova 的季度收入增长了 14.3%。在去年同期，公司每股收益为 0.88 美元。LivaNova 更新了其 2026 财年的指引，预计每股收益为 4.200-4.300 美元。</p>
<p>以下是 LivaNova 电话会议的主要要点：</p>
<ul>
<li>公司将 2026 财年的指引上调至 <strong>7%-8% 的收入增长</strong>，并将调整后的每股收益提高至 <strong>4.20-4.30 美元</strong>，反映出第一季度表现强于预期以及持续的收入增长势头。</li>
<li><strong>心肺领域的强劲表现</strong>：HLM 收入在高个位数增长，得益于 Essenz 升级的采用，消耗品市场份额增加，以及新的生产线（2026 年下半年）和供应商改进，预计将实现低双位数的产出增长和消耗品供应的上行空间。</li>
<li><strong>癫痫的利好因素</strong>：美国医疗保险对 VNS 的新植入物的报销增加约 48%（自 2026 年 1 月 1 日起生效），有利的核心 VNS 研究数据正在改善定价，减少折扣，并预计将随着时间的推移扩大手术渗透率。</li>
<li>OSA 领域的重大监管和临床里程碑——<strong>FDA 对 aura6000 的 PMA 批准</strong> 以及 12 个月的 OSPREY 随机对照试验结果（加上 PolySync 转换数据）大大降低了商业化风险，但短期内的报销不确定性和市场动态使得接受的时间和规模仍不确定。</li>
<li>短期现金和自由现金流压力：现金减少至 <strong>5.4 亿美元</strong>，由于资本支出和营运资金增加，第一季度调整后的自由现金流仅为 <strong>400 万美元</strong>，全年资本支出计划为 <strong>1.2 亿美元</strong>，对短期现金转换造成压力。</li>
</ul>
<h2>LivaNova 股价上涨 15.1%</h2>
<p>周三，纳斯达克代码：LIVN 的股票上涨了 8.67 美元，达到 66.26 美元。该股票的交易量为 1,932,805 股，而其平均交易量为 782,619 股。公司流动比率为 1.16，当前比率为 1.36，债务与股本比率为 0.29。该股票的市值为 36.4 亿美元，市盈率为-14.86，贝塔值为 0.82。该公司的 50 日移动平均价格为 63.97 美元，200 日移动平均价格为 62.03 美元。LivaNova 的 52 周低点为 39.36 美元，52 周高点为 71.92 美元。</p>
<h2>LivaNova 的机构交易</h2>
<p>对冲基金和其他机构投资者最近买卖了该公司的股票。Corient Private Wealth LLC 在第四季度购买了 LivaNova 的新头寸，价值 30.2 万美元。Pacer Advisors Inc.在第四季度将其在 LivaNova 的持股增加了 131.7%。Pacer Advisors Inc.现在拥有 16,661 股该公司的股票，价值 102.5 万美元，此前在该期间又购买了 9,471 股。Invesco Ltd.在第四季度将其在 LivaNova 的持股增加了 4.5%。Invesco Ltd.现在拥有 1,091,086 股该公司的股票，价值 6713.5 万美元，此前在上个季度又购买了 47,323 股。Mercer Global Advisors Inc. ADV 在第四季度收购了 LivaNova 的新头寸，价值 30.6 万美元。最后，田纳西州财政部在第四季度将其在 LivaNova 的持股增加了 44.9%。田纳西州财政部现在拥有 30,304 股该公司的股票，价值 199.1 万美元，此前在该期间又购买了 9,396 股。97.64% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>LivaNova 新闻汇总</h2>
<p>以下是本周影响 LivaNova 的主要新闻：</p>
<ul>
<li>积极情绪：第一季度的每股收益和收入均超出预期——每股收益 0.98 美元，预期为 0.85 美元；收入约为 3.623 亿美元，同比增长约 14%——支持了股价上涨。LivaNova（LIVN）第一季度的收益和收入超出预期。</li>
<li>积极情绪：公司上调 2026 财年指引：调整后的每股收益指引为 4.20-4.30 美元（高于市场共识），收入指引约为 14 亿-15 亿美元——这一上调是积极情绪的主要驱动因素。LivaNova 发布 2026 财年第一季度业绩；上调 2026 财年收入和调整后每股收益指引。</li>
<li>积极情绪：分析师/媒体的报道强调了前景的提升，这支持了股价的上涨，因为投资者重新评估公司更接近于改善后的财年预期。LivaNova 股价在前景提升后上涨。</li>
<li>中性情绪：电话会议材料和幻灯片已发布（对希望了解管理层对增长驱动因素、报销利好和利润前景的评论的投资者有用）。收听电话会议。</li>
<li>中性情绪：交易活动相较于平均交易量激增，表明短期投资者兴趣强烈，但也可能导致市场在消化指引时出现日内波动。MarketBeat LIVN 摘要。</li>
<li>消极情绪：一些报道指出，投资者对指引的某些方面（收入中点与一些预期的差异及前瞻性可见性）反应谨慎，导致其他媒体在早盘交易中报道股价小幅下跌，尽管业绩超出预期。LivaNova 超出预期，但因对指引的担忧股价下跌 2%。</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<p>几位研究分析师最近对 LIVN 股票发布了报告。Piper Sandler 在 2 月 19 日的研究报告中重申了对 LivaNova 的 “增持” 评级，并设定了 85.00 美元的目标价。Stifel Nicolaus 在 2 月 25 日的研究报告中为 LivaNova 设定了 80.00 美元的目标价。巴克莱在 2 月 27 日的报告中将 LivaNova 的目标价从 67.00 美元上调至 73.00 美元，并给予该公司 “与大盘持平” 的评级。Needham &amp; Company LLC 在 2 月 25 日的研究报告中将 LivaNova 的目标价从 64.00 美元上调至 81.00 美元，并给予该股票 “买入” 评级。最后，摩根士丹利在 1 月 9 日的报告中重申了 “中性” 评级，并为 LivaNova 设定了 66.00 美元的目标价。七位分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 74.78 美元。</p>
<p><strong>查看我们最新的 LIVN 研究报告</strong></p>
<h2>关于 LivaNova</h2>
<p>(获取免费报告)</p>
<p>LivaNova plc 是一家全球医疗技术公司，开发和制造心脏外科和神经调节市场的产品和疗法。公司总部位于英国伦敦和美国德克萨斯州休斯顿，LivaNova 为 100 多个国家的医院、诊所和医疗服务提供者提供服务。公司的主要关注点在于通过心肺旁路、心脏保护、循环支持和神经刺激疗法的创新来改善患者护理。</p>
<p>心脏外科业务部门提供一系列用于心肺旁路手术的产品，包括氧合器、心肺机、动脉过滤器、导管和无缝心脏瓣膜。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 LivaNova</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 LivaNova 吗？</h2>
<p>在考虑 LivaNova 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 LivaNova 并不在名单上。</p>
<p>虽然 LivaNova 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LIVN

<p>LivaNova（纳斯达克代码：LIVN）报告的季度每股收益为 0.98 美元，超出预期 0.13 美元，收入为 3.623 亿美元，同比增长 14.3%。该公司将 2026 财年的指引上调至每股收益 4.20–4.30 美元，收入增长 7%–8%，这得益于第一季度的强劲表现。主要增长领域包括心肺和癫痫部门，且医疗保险报销政策出现积极变化。然而，现金流压力有所显现，调整后的自由现金流为 400 万美元。在财报发布后，LivaNova 的股价上涨 15.1%，达到 66.26 美元，反映出投资者的积极情绪</p>

<p>LivaNova (NASDAQ:LIVN - Get Free Report) posted its earnings results on Wednesday. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.13, Briefing.com reports. The company had revenue of $362.30 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova's quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 earnings per share. LivaNova updated its FY 2026 guidance to 4.200-4.300 EPS.</p>
<div class="lb-trans"><p>LivaNova（纳斯达克代码：LIVN - 获取免费报告）于周三发布了其财报。公司报告本季度每股收益为 0.98 美元，超出分析师一致预期的 0.85 美元，超出幅度为 0.13 美元，Briefing.com 报道。公司本季度收入为 3.623 亿美元，而一致预期为 3.4605 亿美元。LivaNova 的股本回报率为 16.54%，净利润率为-17.46%。与去年同期相比，LivaNova 的季度收入增长了 14.3%。在去年同期，公司每股收益为 0.88 美元。LivaNova 更新了其 2026 财年的指引，预计每股收益为 4.200-4.300 美元。</p>
</div><p>Here are the key takeaways from LivaNova's conference call:</p>
<div class="lb-trans"><p>以下是 LivaNova 电话会议的主要要点：</p>
</div><ul>
<li>Company raised full-year 2026 guidance to <strong>7%–8% revenue growth</strong> and increased adjusted EPS to <strong>$4.20–$4.30</strong>, reflecting stronger-than-expected Q1 performance and continued top-line momentum.</li>
<li><strong>Cardiopulmonary strength</strong>: HLM revenue grew in the high teens driven by Essenz upgrade adoption, consumables gained share, and a new manufacturing line (2H26) plus supplier improvements should enable low double-digit output growth and upside to consumables supply.</li>
<li><strong>Epilepsy tailwinds</strong>: U.S. Medicare reimbursement for VNS increased ~48% for new implants (effective Jan 1, 2026) and favorable core VNS study data are improving pricing, reducing discounts, and expected to expand procedure penetration over time.</li>
<li>Major regulatory and clinical milestones in OSA — <strong>FDA PMA approval of the aura6000</strong> and 12‑month OSPREY RCT results (plus PolySync conversion data) materially de‑risk commercialization, but near‑term reimbursement ambiguity and market dynamics leave timing/scale of uptake uncertain.</li>
<li>Near‑term cash and FCF pressure: cash declined to <strong>$540M</strong>, adjusted free cash flow was only <strong>$4M</strong> in Q1 due to higher capital spend and working capital, and full‑year capex is planned at <strong>$120M</strong>, weighing on short‑term cash conversion.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司将 2026 财年的指引上调至 <strong>7%-8% 的收入增长</strong>，并将调整后的每股收益提高至 <strong>4.20-4.30 美元</strong>，反映出第一季度表现强于预期以及持续的收入增长势头。</li>
<li><strong>心肺领域的强劲表现</strong>：HLM 收入在高个位数增长，得益于 Essenz 升级的采用，消耗品市场份额增加，以及新的生产线（2026 年下半年）和供应商改进，预计将实现低双位数的产出增长和消耗品供应的上行空间。</li>
<li><strong>癫痫的利好因素</strong>：美国医疗保险对 VNS 的新植入物的报销增加约 48%（自 2026 年 1 月 1 日起生效），有利的核心 VNS 研究数据正在改善定价，减少折扣，并预计将随着时间的推移扩大手术渗透率。</li>
<li>OSA 领域的重大监管和临床里程碑——<strong>FDA 对 aura6000 的 PMA 批准</strong> 以及 12 个月的 OSPREY 随机对照试验结果（加上 PolySync 转换数据）大大降低了商业化风险，但短期内的报销不确定性和市场动态使得接受的时间和规模仍不确定。</li>
<li>短期现金和自由现金流压力：现金减少至 <strong>5.4 亿美元</strong>，由于资本支出和营运资金增加，第一季度调整后的自由现金流仅为 <strong>400 万美元</strong>，全年资本支出计划为 <strong>1.2 亿美元</strong>，对短期现金转换造成压力。</li>
</ul>
</div><h2>LivaNova Trading Up 15.1%</h2>
<div class="lb-trans"><h2>LivaNova 股价上涨 15.1%</h2>
</div><p>Shares of NASDAQ:LIVN traded up $8.67 during trading on Wednesday, reaching $66.26. The stock had a trading volume of 1,932,805 shares, compared to its average volume of 782,619. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29. The stock has a market cap of $3.64 billion, a P/E ratio of -14.86 and a beta of 0.82. The business has a fifty day moving average price of $63.97 and a 200-day moving average price of $62.03. LivaNova has a fifty-two week low of $39.36 and a fifty-two week high of $71.92.</p>
<div class="lb-trans"><p>周三，纳斯达克代码：LIVN 的股票上涨了 8.67 美元，达到 66.26 美元。该股票的交易量为 1,932,805 股，而其平均交易量为 782,619 股。公司流动比率为 1.16，当前比率为 1.36，债务与股本比率为 0.29。该股票的市值为 36.4 亿美元，市盈率为-14.86，贝塔值为 0.82。该公司的 50 日移动平均价格为 63.97 美元，200 日移动平均价格为 62.03 美元。LivaNova 的 52 周低点为 39.36 美元，52 周高点为 71.92 美元。</p>
</div><h2>Institutional Trading of LivaNova</h2>
<div class="lb-trans"><h2>LivaNova 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC purchased a new position in shares of LivaNova during the 4th quarter worth $302,000. Pacer Advisors Inc. grew its position in shares of LivaNova by 131.7% in the fourth quarter. Pacer Advisors Inc. now owns 16,661 shares of the company's stock valued at $1,025,000 after purchasing an additional 9,471 shares during the period. Invesco Ltd. increased its stake in LivaNova by 4.5% in the fourth quarter. Invesco Ltd. now owns 1,091,086 shares of the company's stock valued at $67,135,000 after purchasing an additional 47,323 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in LivaNova in the fourth quarter valued at $306,000. Finally, State of Tennessee Department of Treasury lifted its position in LivaNova by 44.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company's stock worth $1,991,000 after buying an additional 9,396 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买卖了该公司的股票。Corient Private Wealth LLC 在第四季度购买了 LivaNova 的新头寸，价值 30.2 万美元。Pacer Advisors Inc.在第四季度将其在 LivaNova 的持股增加了 131.7%。Pacer Advisors Inc.现在拥有 16,661 股该公司的股票，价值 102.5 万美元，此前在该期间又购买了 9,471 股。Invesco Ltd.在第四季度将其在 LivaNova 的持股增加了 4.5%。Invesco Ltd.现在拥有 1,091,086 股该公司的股票，价值 6713.5 万美元，此前在上个季度又购买了 47,323 股。Mercer Global Advisors Inc. ADV 在第四季度收购了 LivaNova 的新头寸，价值 30.6 万美元。最后，田纳西州财政部在第四季度将其在 LivaNova 的持股增加了 44.9%。田纳西州财政部现在拥有 30,304 股该公司的股票，价值 199.1 万美元，此前在该期间又购买了 9,396 股。97.64% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>LivaNova News Roundup</h2>
<div class="lb-trans"><h2>LivaNova 新闻汇总</h2>
</div><p>Here are the key news stories impacting LivaNova this week:</p>
<div class="lb-trans"><p>以下是本周影响 LivaNova 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat consensus on both EPS and revenue — EPS $0.98 vs. $0.85 expected; revenue ~$362.3M, up ~14% year‑over‑year — supporting the rally. LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates</li>
<li>Positive Sentiment: Company raised FY‑2026 guidance: adjusted EPS guide of 4.20–4.30 (aboveStreet consensus) and revenue guidance roughly $1.4B–$1.5B — this upward revision is the primary driver of positive sentiment. LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance</li>
<li>Positive Sentiment: Analyst/press coverage highlighted the outlook boost, which supported the stock’s gains as investors re‑price the company closer to the improved FY estimate. LivaNova Shares Rise After Outlook Boost</li>
<li>Neutral Sentiment: Conference-call materials and slides were posted (useful for investors wanting management commentary on growth drivers, reimbursement tailwinds and margin outlook). Listen to Conference Call</li>
<li>Neutral Sentiment: Trading activity spiked versus the average volume, indicating strong short‑term investor interest but also potential for intra‑day volatility as the market digests the guidance. MarketBeat LIVN Summary</li>
<li>Negative Sentiment: Some coverage flagged a cautious investor reaction to aspects of the guidance (revenue midpoint vs. some expectations and forward visibility), which led other outlets to report modest share weakness in early trading despite the beat. LivaNova beats estimates but shares fall 2% on guidance concernsLivaNova (LIVN) beats quarterly expectations but shares slip on cautious guidance reaction</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度的每股收益和收入均超出预期——每股收益 0.98 美元，预期为 0.85 美元；收入约为 3.623 亿美元，同比增长约 14%——支持了股价上涨。LivaNova（LIVN）第一季度的收益和收入超出预期。</li>
<li>积极情绪：公司上调 2026 财年指引：调整后的每股收益指引为 4.20-4.30 美元（高于市场共识），收入指引约为 14 亿-15 亿美元——这一上调是积极情绪的主要驱动因素。LivaNova 发布 2026 财年第一季度业绩；上调 2026 财年收入和调整后每股收益指引。</li>
<li>积极情绪：分析师/媒体的报道强调了前景的提升，这支持了股价的上涨，因为投资者重新评估公司更接近于改善后的财年预期。LivaNova 股价在前景提升后上涨。</li>
<li>中性情绪：电话会议材料和幻灯片已发布（对希望了解管理层对增长驱动因素、报销利好和利润前景的评论的投资者有用）。收听电话会议。</li>
<li>中性情绪：交易活动相较于平均交易量激增，表明短期投资者兴趣强烈，但也可能导致市场在消化指引时出现日内波动。MarketBeat LIVN 摘要。</li>
<li>消极情绪：一些报道指出，投资者对指引的某些方面（收入中点与一些预期的差异及前瞻性可见性）反应谨慎，导致其他媒体在早盘交易中报道股价小幅下跌，尽管业绩超出预期。LivaNova 超出预期，但因对指引的担忧股价下跌 2%。</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research analysts have recently issued reports on LIVN shares. Piper Sandler reaffirmed an &#34;overweight&#34; rating and set a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research note on Wednesday, February 25th. Barclays raised their target price on shares of LivaNova from $67.00 to $73.00 and gave the company an &#34;equal weight&#34; rating in a report on Friday, February 27th. Needham &amp; Company LLC lifted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, February 25th. Finally, The Goldman Sachs Group reaffirmed a &#34;neutral&#34; rating and issued a $66.00 price target on shares of LivaNova in a report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $74.78.</p>
<div class="lb-trans"><p>几位研究分析师最近对 LIVN 股票发布了报告。Piper Sandler 在 2 月 19 日的研究报告中重申了对 LivaNova 的 “增持” 评级，并设定了 85.00 美元的目标价。Stifel Nicolaus 在 2 月 25 日的研究报告中为 LivaNova 设定了 80.00 美元的目标价。巴克莱在 2 月 27 日的报告中将 LivaNova 的目标价从 67.00 美元上调至 73.00 美元，并给予该公司 “与大盘持平” 的评级。Needham &amp; Company LLC 在 2 月 25 日的研究报告中将 LivaNova 的目标价从 64.00 美元上调至 81.00 美元，并给予该股票 “买入” 评级。最后，摩根士丹利在 1 月 9 日的报告中重申了 “中性” 评级，并为 LivaNova 设定了 66.00 美元的目标价。七位分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 74.78 美元。</p>
</div><p><strong>View Our Latest Research Report on LIVN</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LIVN 研究报告</strong></p>
</div><h2>About LivaNova</h2>
<div class="lb-trans"><h2>关于 LivaNova</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.</p>
<div class="lb-trans"><p>LivaNova plc 是一家全球医疗技术公司，开发和制造心脏外科和神经调节市场的产品和疗法。公司总部位于英国伦敦和美国德克萨斯州休斯顿，LivaNova 为 100 多个国家的医院、诊所和医疗服务提供者提供服务。公司的主要关注点在于通过心肺旁路、心脏保护、循环支持和神经刺激疗法的创新来改善患者护理。</p>
</div><p>The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.</p>
<div class="lb-trans"><p>心脏外科业务部门提供一系列用于心肺旁路手术的产品，包括氧合器、心肺机、动脉过滤器、导管和无缝心脏瓣膜。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than LivaNova</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 LivaNova</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LIVN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LivaNova Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 LivaNova 吗？</h2>
</div><p>Before you consider LivaNova, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LivaNova 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 LivaNova 并不在名单上。</p>
</div><p>While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LivaNova 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LivaNova（NASDAQ:LIVN）公布季度财报，每股收益超出预期 0.13 美元